8-K: Chemed Q1 2026 Results and Guidance Hike

Chemed Corporation reported Q1 2026 results with strong VITAS growth, leading to an upward revision of full-year earnings guidance.

Summary

• Consolidated revenue increased 1.6% to $657.5 million.
• Adjusted Diluted EPS rose 0.4% to $5.65.
• VITAS Healthcare segment revenue grew 3.1% to $420.0 million, driven by a 6.9% increase in admissions.
• Roto-Rooter segment revenue declined 0.9% to $237.5 million, impacted by weather-related service disruptions.
• The company repurchased 500,000 shares for $197.7 million during the quarter.
• Full-year 2026 adjusted EPS guidance raised to a range of $24.00 to $24.75.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report because the company raised full-year guidance and demonstrated strong operational recovery in its primary healthcare segment, effectively offsetting minor headwinds in the plumbing division.

Positives

• VITAS Average Daily Census (ADC) increased 2.2% to 22,723.
• VITAS admissions saw strong growth of 6.9%.
• Full-year 2026 guidance for adjusted EPS was increased from the previous $23.25-$24.25 range.
• Strong balance sheet management with $229.6 million remaining in share repurchase authorization.
• Successful acquisition of two Roto-Rooter franchises for $20.6 million to expand market share.

Negatives

• Roto-Rooter revenue declined 0.9% due to lower demand in water restoration and excavation.
• Roto-Rooter Adjusted EBITDA margin fell 218 basis points to 22.5%.
• Unusual weather events caused an estimated $3 million to $4 million revenue loss for Roto-Rooter.
• Marketing expenses for Roto-Rooter exceeded expectations by $2.0 million.
• Consolidated GAAP Diluted EPS decreased 0.4% to $4.84.

Risks

• Medicare Cap billing limitations and potential changes in reimbursement rates.
• Sensitivity to high-acuity patient mix shifts impacting revenue.
• Increased reliance on paid internet marketing for Roto-Rooter lead generation.
• Exposure to weather-related service disruptions affecting plumbing and restoration operations.
• Floating interest rate risk on the new $450 million credit agreement.

Future Outlook

Full-year 2026 adjusted EPS guidance is raised to $24.00-$24.75. VITAS ADC growth is now expected at 4.5%-5.5%, and revenue growth (ex-Medicare Cap) is projected at 6.5%-7.5%. Roto-Rooter revenue growth remains 3.0%-3.5%, though EBITDA margins are slightly lowered due to higher marketing costs.

Management Comments

• VITAS initiatives to return to a normal growth pattern were more quickly successful than originally anticipated.
• Roto-Rooter performed generally within our expectations despite various headwinds.
• The acquisition of Roto-Rooter franchises is part of an ongoing strategy to boost productivity and market share.

Industry Context

StockSavvy.ai notes that Chemed's dual-segment model provides a hedge; while the hospice sector (VITAS) is benefiting from post-Medicare Cap recovery, the home services sector (Roto-Rooter) is facing cyclical headwinds and increased customer acquisition costs common in the current inflationary environment.

Comparison to Industry Standards

• VITAS continues to maintain its position as the nation's largest hospice provider, outperforming smaller regional competitors in scale.
• Roto-Rooter's EBITDA margin of 22.5% remains robust compared to fragmented local plumbing service providers.
• The company's aggressive share repurchase program ($197.7 million in one quarter) reflects a capital allocation strategy focused on shareholder returns, consistent with mature, cash-generative service businesses.

Corporate Governance

Stakeholder Impact

• Shareholders benefit from increased EPS guidance and active share repurchases.
• Customers of Roto-Rooter may see continued service expansion following franchise acquisitions.
• Creditors benefit from the new, well-capitalized credit facility.

Next Steps

• Host investor conference call on April 24, 2026.
• Integrate newly acquired Roto-Rooter franchises in San Francisco and Fort Worth.
• Continue monitoring Medicare Cap cushions across 33 provider numbers.

Key Dates

Recommendation

The combination of upwardly revised guidance, strong hospice segment growth, and aggressive capital return to shareholders makes this a compelling buy for investors seeking stability and growth in the healthcare and services sectors.

Keywords

Chemed, VITAS Healthcare, Roto-Rooter, Hospice, Plumbing Services, Earnings Report, Medicare Cap, Share Repurchase